aod9604 phase 2 trial results weight loss Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks 5-Amino-1-Methylquinolinium 5-Amino-1MQ Vial 10mg – Quantity:1-Bottle
SKU: 81760295680
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9






















